Dan Schell articles
-
Top 2024 Clinical Trial Site Challenges: Staffing & Technology
12/1/2023
Industry experts talk about some of the new challenges facing clinical trial sites in 2024.
-
AI Predictions From The CPHI Annual Report
11/1/2023
The CPhI Annual Report 2023 that was released last month includes insights from 250 global pharma companies and predicts that “within 10 years, over 50% of approved drugs will involve AI in their development and/or manufacturing.”
-
From No Experience To A New Career In Biopharma
11/1/2022
Firsthand accounts from participants in MassBioEd’s new Life Science Apprenticeship Program.
-
What's It Like Being A Termeer Fellow?
4/1/2022
We reached out to four previous Termeer Network Fellows to find out how the program helped them and what they learned. Participants included Sun Altbach, founder and former CEO and president of PIC Therapeutics; Ana Maiques, CEO, Neuroelectrics; Stan Wang, founder & CEO, Thymmune Therapeutuics; and Natalie Yivgi-Ohana, CEO, Minovia Therapeutics.
-
Is Biopharma At An Inflection Point Regarding Digital Transformation?
3/1/2022
Released in late 2021, Deloitte’s, “Gain An Edge With Leapfrog Digital Innovation” report talks about how the biopharma industry is at an inflection point when it comes to digital transformation.
-
Can Caribou Biosciences Top 2021?
3/1/2022
In 2021, much of Rachel Haurwitz’ hard-earned on-the-job training over the past decade culminated in a series of significant milestones that will undoubtably help position Caribou Biosciences for future growth and success.
-
A Cover Feature Four Years In The Making
3/1/2022
I’m not sure what prompted the response from Rachel Haurwitz. It was, after all, a simple “thank you” that I had sent her via LinkedIn back in November 2017 for contributing some comments to our 2018 outlook issue.
-
Thanks To COVID, Your Culture May Need An Overhaul
1/4/2022
This biotech fortified its culture during the pandemic by creating an employee support group, a new performance-management program, a woman-focused initiative, and programs that give days off for volunteering and provide $1200/year for personal and family development goals.
-
Becoming A Clinical-Stage Biotech
9/1/2021
A Q&A with Laura Indolfi, CEO and cofounder of PanTher Therapeutics, which recently closed its Series A funding round and is preparing for its first clinical trials.
-
A Q&A With A Biotech Founder/Entrepreneur
8/2/2021
Since cofounding Kymera Therapeutics, Nello Mainolfi, Ph.D., has served as CSO, CTO, and now is president and CEO. He helped Kymera bring the first ever targeted protein degrader to the clinic, go public in 2020, and land significant partnerships with the likes of GSK, Vertex, and Sanofi.